Currently, while biologic therapies targeting TNF-α and IL-12/23 have demonstrated efficacy in treating both conditions (88, 89), paradoxical effects, such as psoriasis exacerbation in IBD patients (89–93), highlight the need for alternative therapeutic approaches. Here, TNF is linked to inflammatory bowel disease.